Toxoplasma gondii: Difference between revisions

From IDWiki
Toxoplasma gondii
m (typo)
m (changed headings)
Line 1: Line 1:
 
* Protozoan parasite associated with cats and raw beef mostly known for causing opportunistic infections and congenital infections
 
* Protozoan parasite associated with cats and raw beef mostly known for causing opportunistic infections and congenital infections
   
== Microbiology ==
+
== Background ==
  +
=== Microbiology ===
 
 
* Protozoan parasite
 
* Protozoan parasite
 
* Organized into twelve haplotypes
 
* Organized into twelve haplotypes
   
== Epidemiology ==
+
=== Epidemiology ===
 
 
* Zoonotic disease with worldwide distribution
 
* Zoonotic disease with worldwide distribution
 
* Modes of transmission
 
* Modes of transmission
Line 19: Line 18:
 
* There are large parts of South and Central America, as well as Pacific Islands, that have very high seroprevalence [[CiteRef::pappas2009to]]
 
* There are large parts of South and Central America, as well as Pacific Islands, that have very high seroprevalence [[CiteRef::pappas2009to]]
   
== Life Cycle ==
+
=== Life Cycle ===
 
 
* The only definitive hosts are in the Felidae family, essentially housecats and their relatives
 
* The only definitive hosts are in the Felidae family, essentially housecats and their relatives
 
* Intermediate hosts are many, and include birds and rodents
 
* Intermediate hosts are many, and include birds and rodents
Line 29: Line 27:
 
* Bradyzoites are ingested by a cat, completing the life cycle
 
* Bradyzoites are ingested by a cat, completing the life cycle
   
== Pathophysiology ==
+
=== Pathophysiology ===
 
 
* Following ingestion, bradyzoites and sporozoites invade the small intestinal mucosa and develop into tachyzoites within the gut epithelium
 
* Following ingestion, bradyzoites and sporozoites invade the small intestinal mucosa and develop into tachyzoites within the gut epithelium
 
* There, they insert themselves into monocytes and other nucleated cells
 
* There, they insert themselves into monocytes and other nucleated cells
Line 37: Line 34:
   
 
== Clinical Presentation ==
 
== Clinical Presentation ==
 
 
=== Immunocompetent ===
 
=== Immunocompetent ===
 
 
* Asymptomatic in 80% of primary infections
 
* Asymptomatic in 80% of primary infections
 
* Symptoms, when they occur, can involve fever, cervical lymphadenopathy (painless and rubbery), myalgias, and weakness/fatigue
 
* Symptoms, when they occur, can involve fever, cervical lymphadenopathy (painless and rubbery), myalgias, and weakness/fatigue
Line 48: Line 43:
   
 
=== Immunocompromised ===
 
=== Immunocompromised ===
 
 
* May be from primary infection or, more commonly, reactivation
 
* May be from primary infection or, more commonly, reactivation
 
* Unlike in immunocompetent people, it is always a serious infection in the immunocompromised
 
* Unlike in immunocompetent people, it is always a serious infection in the immunocompromised
Line 58: Line 52:
   
 
=== Pregnancy ===
 
=== Pregnancy ===
 
 
* As with other immunocompetent people, it is largely asymptomatic
 
* As with other immunocompetent people, it is largely asymptomatic
 
* Only half of women can identify a significant risk factor [[CiteRef::boyer2011un]]
 
* Only half of women can identify a significant risk factor [[CiteRef::boyer2011un]]
Line 64: Line 57:
   
 
=== Congenital ===
 
=== Congenital ===
  +
* Refer to [[Congenital toxoplasmosis]]
 
* Can be acquired during maternal parasitemia associated with primary infection
 
** Risk of transplacental infection of fetus is lowest in first trimester and highest in third
 
* 85% of infected babies are asymptomatic at birth; 15% symptomatic
 
** Symptom severity increases is highest in first trimester and lowest in third
 
* Classic triad of chorioretinitis (most common), intraparenchymal cerebral calcifications, and hydrocephalus
 
* Others: thrombocytopenia, hepatitis, hepatosplenomegaly, cataracts, strabismus, microphthalmia
 
   
 
== Diagnosis ==
 
== Diagnosis ==
 
 
* Immunocompetent or pregnant women with primary infection: IgG/IgM serology, possibly with avidity testing for pregnant women
 
* Immunocompetent or pregnant women with primary infection: IgG/IgM serology, possibly with avidity testing for pregnant women
 
* Fetus, to rule out congenital infection following maternal primary infection: PCR of amniotic fluid
 
* Fetus, to rule out congenital infection following maternal primary infection: PCR of amniotic fluid
Line 81: Line 67:
   
 
=== Serology ===
 
=== Serology ===
 
 
* ELISA IgG for prior exposure; ELISA IgM for acute infection
 
* ELISA IgG for prior exposure; ELISA IgM for acute infection
 
* IgM titres plateau within 1 month, and IgG within 2-3 months
 
* IgM titres plateau within 1 month, and IgG within 2-3 months
Line 90: Line 75:
   
 
=== PCR ===
 
=== PCR ===
 
 
* Not routinely done
 
* Not routinely done
 
* May be helpful from CSF or vitreous humour
 
* May be helpful from CSF or vitreous humour
Line 96: Line 80:
   
 
== Management ==
 
== Management ==
 
 
* In general, in the setting of known HIV and one or more suspicious lesions, treat empirically for CNS toxoplasmosis and reassess with repeat imaging at around 10 days, at which time there should be some response
 
* In general, in the setting of known HIV and one or more suspicious lesions, treat empirically for CNS toxoplasmosis and reassess with repeat imaging at around 10 days, at which time there should be some response
* First-line is a combination of [[pyrimethamine]] and [[sulfadiazine]]
+
* First-line is a combination of [[Is treated by::pyrimethamine]] and [[Is treated by::sulfadiazine]]
** [[Pyrimethamine]] (with folinic acid) is the backbone
+
** [[Is treated by::Pyrimethamine]] (with folinic acid) is the backbone
** The second agent is typically [[sulfadiazine]], which can be replaced with [[clindamycin]] if needed
+
** The second agent is typically [[Is treated by::sulfadiazine]], which can be replaced with [[Is treated by::clindamycin]] if needed
 
** Encephalitis: pyrimethamine 200 mg load followed by 50-75 mg/day
 
** Encephalitis: pyrimethamine 200 mg load followed by 50-75 mg/day
 
** Infection during pregnancy: pyrimethamine 100 mg daily for 2 days followed by 25 to 50 mg/day
 
** Infection during pregnancy: pyrimethamine 100 mg daily for 2 days followed by 25 to 50 mg/day
 
* Alternatives
 
* Alternatives
** [[TMP-SMX]]
+
** [[Is treated by::TMP-SMX]]
** [[Atovaquone]]
+
** [[Is treated by::Atovaquone]]
   
 
=== HIV ===
 
=== HIV ===
 
* [[Is treated by::Pyrimethamine]] 200 mg PO once, followed by dose based on body weight:
 
 
** Body weight ≤60 kg: [[Is treated by::pyrimethamine]] 50 mg PO daily + [[Is treated by::sulfadiazine]] 1000 mg PO q6h + leucovorin 10–25 mg PO daily (can increase to 50 mg daily or BID)
* [[Pyrimethamine]] 200 mg PO once, followed by dose based on body weight:
 
** Body weight ≤60 kg: [[pyrimethamine]] 50 mg PO daily + [[sulfadiazine]] 1000 mg PO q6h + leucovorin 10–25 mg PO daily (can increase to 50 mg daily or BID)
+
** Body weight >60 kg: [[Is treated by::pyrimethamine]] 75 mg PO daily + [[Is treated by::sulfadiazine]] 1500 mg PO q6h + leucovorin 10–25 mg PO daily (can increase to 50 mg daily or BID)
** Body weight >60 kg: [[pyrimethamine]] 75 mg PO daily + [[sulfadiazine]] 1500 mg PO q6h + leucovorin 10–25 mg PO daily (can increase to 50 mg daily or BID)
 
 
* Alternatives
 
* Alternatives
** [[Pyrimethamine]] (with leucovorin) plus [[clindamycin]] 600 mg IV or PO q6h
+
** [[Is treated by::Pyrimethamine]] (with leucovorin) plus [[Is treated by::clindamycin]] 600 mg IV or PO q6h
** [[TMP-SMX]] (TMP 5 mg/kg and SMX 25 mg/kg) (IV or PO) BID
+
** [[Is treated by::TMP-SMX]] (TMP 5 mg/kg and SMX 25 mg/kg) (IV or PO) BID
** [[Atovaquone]] 1500 mg PO BID + [[pyrimethamine]] (leucovorin)
+
** [[Is treated by::Atovaquone]] 1500 mg PO BID + [[Is treated by::pyrimethamine]] (leucovorin)
** [[Atovaquone]] 1500 mg PO BID + [[sulfadiazine]]
+
** [[Is treated by::Atovaquone]] 1500 mg PO BID + [[Is treated by::sulfadiazine]]
** [[Atovaquone]] 1500 mg PO BID
+
** [[Is treated by::Atovaquone]] 1500 mg PO BID
   
 
=== Pregnancy ===
 
=== Pregnancy ===
 
* [[Is treated by::Pyrimethamine]] is relatively contraindicated in pregnancy as it is toxic to the young fetus
 
* [[Pyrimethamine]] is relatively contraindicated in pregnancy as it is toxic to the young fetus
 
 
* If life-threatening, should likely need treatment and consider abortion (if early in pregnancy)
 
* If life-threatening, should likely need treatment and consider abortion (if early in pregnancy)
* [[Spiromycin]] is safe, and decreases transmission to fetus, but is not enough to treat CNS disease
+
* [[Is treated by::Spiromycin]] is safe, and decreases transmission to fetus, but is not enough to treat CNS disease
   
 
== Prevention ==
 
== Prevention ==
 
 
* Cats: hand hygiene after handling cat, use gloves and wash hands when handling litter, wash litter tray with hot >60ºC water, keep litter out of kitchen
 
* Cats: hand hygiene after handling cat, use gloves and wash hands when handling litter, wash litter tray with hot >60ºC water, keep litter out of kitchen
 
* Soil: use gloves for gardening, wash hands after soil contact
 
* Soil: use gloves for gardening, wash hands after soil contact
Line 133: Line 113:
   
 
== Further Reading ==
 
== Further Reading ==
 
 
* Epidemiology of and Diagnostic Strategies for Toxoplasmosis. ''Clin Microbiol Rev''. 2012;25(2):264. doi: [[https://doi.org/10.1128/CMR.05013-11 10.1128/CMR.05013-11]]
 
* Epidemiology of and Diagnostic Strategies for Toxoplasmosis. ''Clin Microbiol Rev''. 2012;25(2):264. doi: [[https://doi.org/10.1128/CMR.05013-11 10.1128/CMR.05013-11]]
   

Revision as of 21:12, 8 February 2020

  • Protozoan parasite associated with cats and raw beef mostly known for causing opportunistic infections and congenital infections

Background

Microbiology

  • Protozoan parasite
  • Organized into twelve haplotypes

Epidemiology

  • Zoonotic disease with worldwide distribution
  • Modes of transmission
    • Ingesting tissue cysts in meat, or oocytes in food or water
    • Solid-organ transplantation, especially heart
    • Vertical or transplacental transmission
    • Case reports of lab-acquired needlestick transmission
    • Theoretical risk with blood transfusion
  • Seroprevalence around 10-18% in Canada 12
    • As high as 60% in Nunavut, however 3
  • There are large parts of South and Central America, as well as Pacific Islands, that have very high seroprevalence 4

Life Cycle

  • The only definitive hosts are in the Felidae family, essentially housecats and their relatives
  • Intermediate hosts are many, and include birds and rodents
  • An infected cat sheds oocytes into the environment (for 1 to 3 weeks), where they spend 1 to 5 days sporulating
    • Each sporulated oocyst contains two sporocysts, and each sporocyst contains four sporozoites
  • Intermediate hosts ingest the sporozoites, where they mature into tachyzoites
  • Tachyzoites migrate to brain and muscle, where they encyst and become bradyzoites
  • Bradyzoites are ingested by a cat, completing the life cycle

Pathophysiology

  • Following ingestion, bradyzoites and sporozoites invade the small intestinal mucosa and develop into tachyzoites within the gut epithelium
  • There, they insert themselves into monocytes and other nucleated cells
  • Infected cells travel throughout the body, carrying the tachyzoite with them
  • Infection triggers a Th-1 response

Clinical Presentation

Immunocompetent

  • Asymptomatic in 80% of primary infections
  • Symptoms, when they occur, can involve fever, cervical lymphadenopathy (painless and rubbery), myalgias, and weakness/fatigue
  • Can also cause chorioretinitis
  • Severity of illness depends in part on genotype, with strain II in North America and Europe being less severe
    • Rarely, unusual strains may cause pneumonitis, myocarditis, meningoencephalitis, or polymyositis, and can lead to death

Immunocompromised

  • May be from primary infection or, more commonly, reactivation
  • Unlike in immunocompetent people, it is always a serious infection in the immunocompromised
  • Major risk factor is cellular immunodeficiency, as in HIV and some immunosuppressive medications
    • In HIV, beware with CD4 < 100
  • Typically presents with CNS involvement as encephalitis
    • Symptoms include fever, headache, lethargy, incoordination, ataxia, hemiparesis, loss of memory, dementia, or seizures
  • Can also present with pneumonitis (especially with bone marrow transplant), chorioretinitis, or myocarditis, and rarely involves essentially any other organ

Pregnancy

  • As with other immunocompetent people, it is largely asymptomatic
  • Only half of women can identify a significant risk factor 5
  • Risk of transmission to fetus is with parasitemia associated with primary infection, so women who are seropositive are not at risk of having a child with congenital infection

Congenital

Diagnosis

  • Immunocompetent or pregnant women with primary infection: IgG/IgM serology, possibly with avidity testing for pregnant women
  • Fetus, to rule out congenital infection following maternal primary infection: PCR of amniotic fluid
  • Newborn, to rule out congenital infection: PCR of placenta or cord, or serology
  • Immunocompromised patient, to diagnose cerebral or disseminated disease: PCR of blood, CSF, BAL, or tissue
  • Patient with chorioretinitis: Parallel serologies from aqueous humour and serum, or PCR of aqueous humour

Serology

  • ELISA IgG for prior exposure; ELISA IgM for acute infection
  • IgM titres plateau within 1 month, and IgG within 2-3 months
  • IgM is still detectable for months or years after infection
  • IgM avidity testing can help to assess how recently the infection was acquired
    • Provides a measure of how tightly the antibodies bind, which is highest in early infection
    • A high avidity ratio (weak binding) suggests that the infection was acquired at least 4 months prior

PCR

  • Not routinely done
  • May be helpful from CSF or vitreous humour
  • Not helpful on brain biopsy tissue

Management

  • In general, in the setting of known HIV and one or more suspicious lesions, treat empirically for CNS toxoplasmosis and reassess with repeat imaging at around 10 days, at which time there should be some response
  • First-line is a combination of pyrimethamine and sulfadiazine
    • Pyrimethamine (with folinic acid) is the backbone
    • The second agent is typically sulfadiazine, which can be replaced with clindamycin if needed
    • Encephalitis: pyrimethamine 200 mg load followed by 50-75 mg/day
    • Infection during pregnancy: pyrimethamine 100 mg daily for 2 days followed by 25 to 50 mg/day
  • Alternatives

HIV

Pregnancy

  • Pyrimethamine is relatively contraindicated in pregnancy as it is toxic to the young fetus
  • If life-threatening, should likely need treatment and consider abortion (if early in pregnancy)
  • Spiromycin is safe, and decreases transmission to fetus, but is not enough to treat CNS disease

Prevention

  • Cats: hand hygiene after handling cat, use gloves and wash hands when handling litter, wash litter tray with hot >60ºC water, keep litter out of kitchen
  • Soil: use gloves for gardening, wash hands after soil contact
  • Water: avoid tap water in highly endemic countries, avoid ingestion of lake and river water
  • Food: avoid raw oysters/clams/mussels, wash all vegetables/fruits/herbs, cook meat well down

Further Reading

  • Epidemiology of and Diagnostic Strategies for Toxoplasmosis. Clin Microbiol Rev. 2012;25(2):264. doi: [10.1128/CMR.05013-11]

References

  1. ^  Samar Shuhaiber, Gideon Koren, Rada Boskovic, Thomas R Einarson, Offie Porat Soldin, Adrienne Einarson. Seroprevalence of Toxoplasma gondiiinfection among veterinary staff in Ontario, Canada (2002): Implications for teratogenic risk. BMC Infectious Diseases. 2003;3(1). doi:10.1186/1471-2334-3-8.
  2. ^  EL Ford-Jones, I Kitai, M Corey, R Notenboom, N Hollander, E Kelly, H Akoury, G Ryan, I Kyle, R Gold. Seroprevalence of Toxoplasma Antibody in a Toronto Population. Canadian Journal of Infectious Diseases. 1996;7(5):326-328. doi:10.1155/1996/172651.
  3. ^  V. Messier, B. Lévesque, J.-F. Proulx, L. Rochette, M. D. Libman, B. J. Ward, B. Serhir, M. Couillard, N. H. Ogden, É. Dewailly, B. Hubert, S. Déry, C. Barthe, D. Murphy, B. Dixon. Seroprevalence of Toxoplasma gondii Among Nunavik Inuit (Canada). Zoonoses and Public Health. 2009;56(4):188-197. doi:10.1111/j.1863-2378.2008.01177.x.
  4. ^  Georgios Pappas, Nikos Roussos, Matthew E. Falagas. Toxoplasmosis snapshots: Global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis. International Journal for Parasitology. 2009;39(12):1385-1394. doi:10.1016/j.ijpara.2009.04.003.
  5. ^  K. Boyer, D. Hill, E. Mui, K. Wroblewski, T. Karrison, J. P. Dubey, M. Sautter, A. G. Noble, S. Withers, C. Swisher, P. Heydemann, T. Hosten, J. Babiarz, D. Lee, P. Meier, R. McLeod. Unrecognized Ingestion of Toxoplasma gondii Oocysts Leads to Congenital Toxoplasmosis and Causes Epidemics in North America. Clinical Infectious Diseases. 2011;53(11):1081-1089. doi:10.1093/cid/cir667.